NCT01096602View on ClinicalTrials.gov

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2024

Conditions
Acute Myelogenous LeukemiaAML
Interventions
BIOLOGICAL

DC AML Vaccine

Group 1: 2-3 doses of the vaccine at 4 week intervals

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Medivation, Inc.

INDUSTRY

collaborator

The Leukemia and Lymphoma Society

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER